Twist Bioscience: DNA Research Tools Put Fresh Spin On Drug Discovery
Executive Summary
Speed and efficiency are fundamental to the success of today’s biopharmaceutical enterprise, but the hunt is still on for transformative technologies to boost pipeline productivity and growth. One answer may lie in the arrival of replicable, synthetic versions of DNA.
You may also be interested in...
Twist's Unconventional Approach, Adding Value One Rung At A Time
Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Bioscience, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.
More Antibodies Than Stars: Overhauling Antibody Drug Discovery
Antiverse co-founder and CEO Murat Tunaboylu, one of In Vivo’s 2022 Rising Leaders, on defining success and why software engineers should consider a career transition to life sciences.
Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.